Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.

By C. Fribbens, B. O’Leary, L. Kilburn, S. Hrebien, I. Garcia-Murillas, M. Beaney, M. Cristofanilli, F. André, S. Loi, S. Loibl and 7 more. Journal of Clinical Oncology, 2016

639 citations recorded by the source corpus.

Subfields: Cancer Research, Genetics, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/ad83ee94ec2d007eae96c0e335fc7f77aa46a7e3

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. J. Reis-Filho
2. Carlos L. Arteaga
3. Lisa A. Carey
4. A. Hanker
5. D. Sudhan

In Genetics

1. J. Reis-Filho
2. Carlos L. Arteaga
3. Ronglai Shen

In Pulmonary and Respiratory Medicine

1. J. Baselga
2. Carlos L. Arteaga
3. Marc Ladanyi
4. A. Hanker
5. D. Sudhan

Citations in the corpus

• Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: A report from the ESMO Precision Medicine Working Group. (2020, background): “ESR1 mutations occur in around 20% of patients previously treated with aromatase inhibitors and are associated with response to selective estrogen receptor degraders.(74) Nevertheless, these data are preliminary and cannot be used in daily practice.”
• De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 (2018, background): “Molecular mechanisms of resistance to therapy Activating mutations in the estrogen receptor ESR1 gene arise in 30%–40% of recurrences on AI therapy and likely account for resistance to AI treatment in those cases [81].”
• Overcoming Endocrine Resistance in Breast Cancer (2020, positive): “The prevalence of ESR1 mutations in plasma ctDNA in similar populations is even higher (Fribbens et al., 2016; Schiavon et al., 2015).”
• 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020, background): “74).(87) Despite promising preclinical data and statistical trends, the ESCAT scale for ESR1 mutations is tier II.”
• The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers (2018, background): “On the other hand, and reflecting the impact of prior therapy, ligand binding domain mutations in ESR1 were present in 18% of HRHER2 patients whose sequenced tumor specimens were collected after endocrine therapy (n = 128 of 692) (Chandarlapaty et al., 2016; Fribbens et al., 2016; Robinson et al., 2”